Data on the survival of patients with metastatic conjunctival melanoma is limited but seems poor, with a median overall survival of 5–8 months, although survival is likely to have improved after BRAF(/MEK) inhibitors and immune checkpoint inhibitors became available [53,92]. Here, MAP2K7 is linked to malignant conjunctival melanoma.